Clarity for Cardiome as Merck Returns Rights to Vernakalant
By Catherine Shaffer
Wednesday, September 26, 2012
Six months of uncertainty have come to an end for Cardiome Pharma Corp., as Merck & Co. Inc. announced it would hand global marketing and development rights for I.V. and oral formulations of heart drug vernakalant back to the Vancouver, British Columbia-based company.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.